SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane

BACKGROUND: HER2-positive breast cancer is usually associated to the more aggressive progression and the worse prognosis, but the mechanism underlying the innate resistance to HER2-targeted therapy remains elusive. The scaffold protein SH3-domain-binding glutamic acid-rich protein-like protein (SH3B...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hui, Zhang, Mingming, Wei, Yanli, Haider, Farhan, Lin, Yitong, Guan, Wen, Liu, Yanbin, Zhang, Shaoyang, Yuan, Ronghua, Yang, Xia, Yang, Shulan, Wang, Haihe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204297/
https://www.ncbi.nlm.nih.gov/pubmed/32381043
http://dx.doi.org/10.1186/s13046-020-01577-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204297/
https://www.ncbi.nlm.nih.gov/pubmed/32381043
http://dx.doi.org/10.1186/s13046-020-01577-z

Ejemplares similares